| Autor: |
Antal, CE, Hudson, AM, Kang, E, Zanca, C, Wirth, C, Stephenson, NL, Trotter, EW, Gallegos, LL, Miller, CJ, Furnari, FB, Hunter, T, Brognard, J, Newton, AC |
| Jazyk: |
angličtina |
| Rok vydání: |
2015 |
| Zdroj: |
Antal, CE; Hudson, AM; Kang, E; Zanca, C; Wirth, C; Stephenson, NL; et al.(2015). Cancer-associated protein kinase C mutations reveal kinase's role as tumor suppressor. Cell, 160(3), 489-502. doi: 10.1016/j.cell.2015.01.001. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/5903j9zb |
| DOI: |
10.1016/j.cell.2015.01.001. |
| Popis: |
© 2015 Elsevier Inc.Protein kinase C (PKC) isozymes have remained elusive cancer targets despite the unambiguous tumor promoting function of their potent ligands, phorbol esters, and the prevalence of their mutations. We analyzed 8% of PKC mutations identified in human cancers and found that, surprisingly, most were loss of function and none were activating. Loss-of-function mutations occurred in all PKC subgroups and impeded second-messenger binding, phosphorylation, or catalysis. Correction of a loss-of-function PKCβ mutation by CRISPR-mediated genome editing in a patient-derived colon cancer cell line suppressed anchorage-independent growth and reduced tumor growth in a xenograft model. Hemizygous deletion promoted anchorage-independent growth, revealing that PKCβ is haploinsufficient for tumor suppression. Several mutations were dominant negative, suppressing global PKC signaling output, and bioinformatic analysis suggested that PKC mutations cooperate with co-occurring mutations in cancer drivers. These data establish that PKC isozymes generally function as tumor suppressors, indicating that therapies should focus on restoring, not inhibiting, PKC activity. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
